GlassScriptPhysician profile
Gary V Burton
NPI 1316968761
$9,696.90
in general payments reported to CMS, 2019-2025
54 companies · $3,313 in 2025
The $3,313 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $163 · 2021: $114 · 2022: $795 · 2023: $1,939 · 2024: $3,064 · 2025: $3,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,993 · Long Term Medical Supply Or Device Loan: $2,115 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,992.56 |
| Long Term Medical Supply Or Device Loan | $2,114.51 |
| Education | $209.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,383.93 | 2019-2025 | |
| Daiichi Sankyo INC. | $871.92 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Merck Sharp & Dohme LLC | $497.79 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $462.42 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $404.10 | 2022-2025 | Calquence, Enhertu, Lynparza |
| Pfizer INC. | $363.80 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $305.34 | 2020-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $275.83 | 2022-2025 | Darzalex, Talvey, Erleada |
| Gilead Sciences, INC. | $255.30 | 2019-2025 | Trodelvy |
| Puma Biotechnology, INC. | $219.57 | 2019-2025 | Nerlynx |
| Genentech USA, INC. | $163.49 | 2019-2025 | Tecentriq, Phesgo, Itovebi |
| Stemline Therapeutics INC. | $158.96 | 2023-2025 | Orserdu |
| Springworks Therapeutics, INC. | $153.02 | 2024-2025 | Ogsiveo |
| Astellas Pharma US INC | $152.64 | 2022-2025 | Vyloy, Xtandi, Padcev |
| Amgen INC. | $146.56 | 2019-2024 | Prolia, Xgeva |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $138.92 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Celgene Corporation | $136.97 | 2022-2025 | Reblozyl, Pomalyst, Breyanzi |
| Seagen INC. | $128.44 | 2022-2023 | Adcetris, Tukysa |
| Eisai INC. | $118.34 | 2019-2023 | |
| Lilly USA, LLC | $113.73 | 2023-2024 | Retevmo |
| Rigel Pharmaceuticals, INC. | $93.79 | 2024 | Rezlidhia, Tavalisse |
| Recordati_rare_diseases_inc. | $79.46 | 2024-2025 | Sylvant |
| Pharmacyclics LLC, An Abbvie Company | $79.12 | 2023 | Epkinly, Imbruvica |
| Regeneron Healthcare Solutions, INC. | $68.43 | 2022-2024 | Libtayo |
| Beone Medicines USA, INC. | $60.53 | 2025 | Brukinsa |
| Karyopharm Therapeutics INC. | $60.09 | 2023-2025 | Xpovio |
| Genmab U.S., INC. | $56.51 | 2023-2025 | Epkinly, Tivdak |
| Eli Lilly and Company | $54.02 | 2023 | |
| Kite Pharma, INC. | $53.69 | 2020-2023 | |
| Beigene USA, INC. | $53.43 | 2023-2025 | Brukinsa |
| Genzyme Corporation | $51.11 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $40.78 | 2023-2024 | Ingrezza |
| Caris Mpi, INC. | $40.40 | 2025 | Mi Cancer Seek |
| Aveo Pharmaceuticals, INC. | $35.86 | 2023-2025 | Fotivda |
| Incyte Corporation | $35.37 | 2023-2025 | Jakafi, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $34.26 | 2024-2025 | Iclusig, Ninlaro |
| Alexion Pharmaceuticals, INC. | $33.56 | 2024 | Ultomiris |
| Acrotech Biopharma INC. | $31.66 | 2022-2024 | Beleodaq |
| Tempus Ai, INC | $29.98 | 2024 | Xt Cdx |
| Tesaro, INC. | $25.54 | 2019 | |
| Exelixis INC. | $24.01 | 2024 | Cabometyx |
| Apellis Pharmaceuticals, INC. | $23.87 | 2025 | |
| Servier Pharmaceuticals LLC | $20.51 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $20.15 | 2019 | |
| Menarini Silicon Biosystems, INC. | $19.37 | 2023 | Cellsearch |
| Bayer Healthcare Pharmaceuticals INC. | $18.78 | 2023 | |
| Pharmaessentia USA Corporation | $18.64 | 2025 | Besremi |
| G1 Therapeutics, INC. | $15.50 | 2022 | |
| Secura Bio, INC. | $15.22 | 2024 | Copiktra |
| Emd Serono, INC. | $14.71 | 2024 | |
| Sobi, INC | $13.79 | 2025 | |
| Mirati Therapeutics, INC. | $12.73 | 2023 | Krazati |
| Teva Pharmaceuticals USA, INC. | $10.96 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Burton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.